RNA vs ZTS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

RNA

51.6
AI Score
VS
RNA Wins

ZTS

40.9
AI Score

Investment Advisor Scores

RNA

52score
Recommendation
HOLD

ZTS

41score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric RNA ZTS Winner
Forward P/E 0 13.2979 Tie
PEG Ratio 0 14.7776 Tie
Revenue Growth -21.9% -1.3% ZTS
Earnings Growth 0.0% -11.8% RNA
Tradestie Score 51.6/100 40.9/100 RNA
Profit Margin -184.1% 26.4% ZTS
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

RNA 1M: +2.6% · 3M: -35.5% ZTS 1M: +10.2% · 3M: +8.0%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 39

RSI (14): 39.3 · Price: $7.95

ZTS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.9% over 20 days), RSI 55

RSI (14): 55.0 · Price: $81.90

Fundamentals Snapshot

Metric RNA ZTS
Market Cap — —
Forward P/E -1.4 12.9
Trailing P/E — 14.0
Revenue (TTM) — —
Revenue Growth -0.2% 0.0%
Gross Margin -0.6% 0.7%
Operating Margin -7.5% 0.4%
EPS -5.44 5.88
Dividend Yield — 0.03%

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.